Analyzing T Cell Responses How to analyze cellular immune responses against tumor associated antigens

Active specific immunotherapy is a promising but investigational modality in the management of cancer patients. Currently, several different cancer vaccine formulations such as peptides, proteins, antigen-pulsed dendritic cells, whole tumor cells, etc. in combination with various adjuvants and carri...

Full description

Bibliographic Details
Other Authors: Nagorsen, Dirk (Editor), Marincola, Francesco M. (Editor)
Format: eBook
Language:English
Published: Dordrecht Springer Netherlands 2005, 2005
Edition:1st ed. 2005
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
Table of Contents:
  • Monitoring Antigen-Specific T Cell Responses
  • Tumor Associated Antigens
  • Immune Escape, Tumor induced immune suppression and immune escape: Mechanisms and Possible Solutions
  • Virus Specific T-Cell Responses
  • Cytotoxicity Assays Killer Lymphocytes in Cancer
  • Monitoring T Cell Proliferation
  • Elispot Assay, Assessment of Cellular Immune Responses to Anti-Cancer Vaccines
  • Modified Elispot, Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
  • Intracellular Cytokine Staining, Cytokine flow cytometry for characterization of tumor-specific T cell responses
  • Cytometric Cytokine Secretion Assay, Detection and Isolation of Antigen-Specific T Cells
  • Peptide/MHC Tetramer Analysis
  • In Situ MHC Tetramer Staining, In Situ Tetramers
  • MHC-IG Dimeric Molecules, Dimers - MHC-IG dimeric molecules for the analysis of antigen-specific T cell responses
  • TCR Analyses, T-cell receptor CDR3 analysis: Molecular fingerprinting of the T-cell receptor repertoire
  • Peptide/HLA-GFP Complexes, Detection of Antigen-Specific T Cells by Acquisition of Peptide/Hla-Gfp Complexes
  • QRT-PCR, Quantitative RT-PCR for the Analysis of T cell Responses in Immunized Cancer Patients
  • Microarrays, Gene expression profiling approaches for the monitoring of anti-cancer immune responses
  • Concluding Remarks